aTYR PHARMA INC — Director's Dealing 2019

Apr 16, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: aTYR PHARMA INC (LIFE)
CIK: 0001339970
Period of Report: 2019-04-12

Reporting Person: SCHIMMEL PAUL (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-04-12	Common Stock	A	1848428	$0.541	Acquired	2570242	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	40440	Direct
Common Stock	882302	Indirect

Footnotes

F1: These shares are owned directly by Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. The Reporting Person is the sole owner of the Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel.

F2: Represents shares acquired in a registered direct offering pursuant to a Securities Purchase Agreement, dated April 10, 2019, entered between aTyr Pharma, Inc. and the investors named therein. Pursuant to the terms of the Securities Purchase Agreement, investors purchased shares of common stock at a purchase price of $0.541 per share.

F3: These shares are owned directly by Schimmel Revocable Trust U/A Dtd 9/6/2000. The Reporting Person and his spouse are trustees of the Schimmel Revocable Trust U/A Dtd 9/6/2000.